Related Experiment Videos
Gene therapy for hypertension: the preclinical data.
1Department of Physiology and Functional Genomics, College of Medicine, University of Florida, Gainesville, Florida 32610, USA.
Methods in Enzymology
|March 9, 2002
Summary
Gene therapy offers a promising approach for hypertension treatment, potentially providing longer-lasting effects than current drugs. Preclinical studies show gene therapy can effectively lower blood pressure for weeks to months.
Area of Science:
- Cardiovascular Research
- Gene Therapy
- Hypertension Treatment
Background:
- Current hypertension drugs have limitations including short duration of action, side effects, and lack of specificity.
- Gene therapy presents a potential alternative for sustained and specific blood pressure control.
Purpose of the Study:
- To review preclinical gene therapy approaches for hypertension, focusing on gene transfer and antisense strategies.
- To evaluate the efficacy and duration of blood pressure reduction achieved through various gene therapy methods in preclinical models.
Main Methods:
- Gene transfer of vasodilator proteins (e.g., kallikrein, atrial natriuretic peptide) into rat models.
- Antisense strategies targeting genes like angiotensinogen and angiotensin type 1 receptor using oligodeoxynucleotides or viral vectors.
Main Results:
- Gene transfer of vasodilators lowered blood pressure in rats for 3-12 weeks.
- Antisense approaches demonstrated blood pressure reduction lasting from days to months in various hypertension models.
- Adeno-associated virus delivery of antisense to AT1 receptors showed sustained hypertension reduction up to 6 months in rodents.
Conclusions:
- Preclinical data strongly support gene therapy, particularly antisense strategies, as a viable treatment for hypertension.
- Further investigation, including Phase I trials for antisense oligodeoxynucleotides and adeno-associated virus vectors, is warranted.